MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

@article{Brandes2008MGMTPM,
  title={MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.},
  author={Alba A Brandes and Enrico Franceschi and Alicia Tosoni and Valeria Blatt and Annalisa Pession and G. Tallini and Roberta Bertorelle and Stefania Bartolini and Fabio Calbucci and Alvaro Andreoli and Giampiero Frezza and Marco Leonardi and Federica Spagnolli and M. Ermani},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 13},
  pages={2192-7}
}
PURPOSE Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy. The radiologic images obtained in this setting can be difficult to interpret since they may show radiation-induced pseudoprogression (psPD) rather than disease progression. METHODS Patients with histologically confirmed GBM underwent radiotherapy plus continuous daily temozolomide (75 mg/m(2)/d), followed by 12 maintenance… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS